Sweet syndrome is a rare inflammatory skin condition marked by the sudden appearance of painful red bumps or raised patches on the skin, usually alongside a fever. Its formal medical name, acute febrile neutrophilic dermatosis, describes what’s happening under the surface: a type of white blood cell called a neutrophil floods into the upper layer of the skin in unusually large numbers, causing swelling, redness, and tenderness. The condition was first described by dermatologist Robert Douglas Sweet in 1964, and while it can look alarming, it typically responds well to treatment.
What Sweet Syndrome Looks and Feels Like
The hallmark of Sweet syndrome is the abrupt onset of well-defined, tender plaques or nodules on the skin. These lesions are red or violet, can range from small bumps to larger raised patches, and often feel warm and painful to the touch. They most commonly appear on the upper arms, but can also show up on the face, neck, chest, back, and legs. The distribution tends to be asymmetric, meaning one side of the body may be more affected than the other.
Beyond the classic raised patches, some people develop lesions that look pustular, blistered, or bullous (fluid-filled). Occasionally, lesions resemble a bullseye or target shape. Oral or genital sores are rare but possible.
The skin symptoms rarely arrive alone. Most people also experience fever, joint pain, and headaches. Eye inflammation can occur as well. These systemic symptoms, combined with the dramatic-looking skin lesions, often prompt an urgent visit to a doctor, which is appropriate since several other conditions can mimic the appearance.
Three Clinical Subtypes
Sweet syndrome is classified into three subtypes based on what triggers it.
- Classical (idiopathic): The most common form. No clear underlying cause is identified. It tends to occur more often in women and sometimes follows an upper respiratory or gastrointestinal infection.
- Malignancy-associated: This form develops in the setting of cancer, most often blood cancers. Acute myeloid leukemia and myelodysplastic syndrome are the two most frequently linked malignancies. Multiple myeloma and, less commonly, solid tumors like liver cancer have also been reported.
- Drug-induced: Certain medications can trigger the condition. A well-known culprit is granulocyte colony-stimulating factor (G-CSF), a drug used to boost white blood cell production after chemotherapy. Certain antibiotics, including sulfamethoxazole/trimethoprim and some fluoroquinolones, have also been implicated.
Knowing which subtype a person has matters because it shapes what happens next. In the malignancy-associated form, the skin lesions may be the first visible sign of an underlying blood cancer, so doctors will often order blood work and a bone marrow biopsy when Sweet syndrome is diagnosed in someone without an obvious trigger.
What Causes It
The exact mechanism behind Sweet syndrome is not fully understood, but it is considered multifactorial. Dysregulated immune signaling plays a central role: certain chemical messengers in the immune system appear to activate neutrophils and drive them into the skin in excessive numbers. Genetic susceptibility, infections, autoimmune disorders, cancers, and medications can all serve as triggers that set this cascade in motion.
In the malignancy-associated subtype, blood cancers are the dominant link. One study found that among patients with cancer-related Sweet syndrome, acute myeloid leukemia accounted for 44% of cases and myelodysplastic syndrome another 44%. These cancers directly affect the bone marrow, where neutrophils are produced, which likely explains the connection. Solid tumors are far less common triggers.
How It’s Diagnosed
Diagnosis relies on a combination of clinical features and a skin biopsy. A set of major and minor criteria guides the process. Both major criteria must be met, along with at least two of the minor ones.
The two major criteria are the abrupt onset of tender red plaques or nodules and biopsy evidence showing a dense concentration of neutrophils in the upper skin layer without signs of blood vessel inflammation (a distinction that helps rule out vasculitis). The minor criteria include fever, abnormal blood work showing elevated white blood cells (particularly neutrophils), elevated markers of inflammation, and a rapid response to corticosteroid treatment. That last point is itself a diagnostic clue: if the lesions clear dramatically within days of starting steroids, it strongly supports the diagnosis.
Treatment and What to Expect
Corticosteroids are the first-line treatment, and the response is often described as dramatic. Skin lesions and systemic symptoms like fever and joint pain typically begin improving within days of starting oral corticosteroids. A standard course involves a moderate dose tapered over about three weeks.
For people who can’t tolerate corticosteroids or who have recurrent episodes requiring repeated courses, several steroid-sparing alternatives exist. Colchicine, dapsone, and potassium iodide are the best-supported options, though the evidence behind them comes mostly from case series rather than large clinical trials. In the drug-induced form, stopping the offending medication is often enough to resolve the condition, sometimes combined with a short course of steroids to speed things along.
When Sweet syndrome is linked to an underlying cancer, treating the cancer itself is essential. The skin lesions may flare when the cancer is active and improve when it’s in remission.
Recurrence and Long-Term Outlook
Sweet syndrome is not a one-and-done condition for everyone. Recurrence is common, particularly in the classical form. Some people experience repeated flares over months or years, often without a clear trigger for each episode. Each flare typically responds to treatment just as well as the first, but the pattern of recurrence can be frustrating.
The skin lesions themselves generally heal without scarring, though some people notice temporary changes in skin color at the sites of previous lesions. The long-term outlook depends largely on the subtype. Classical Sweet syndrome carries no increased risk of serious complications on its own. In malignancy-associated cases, the prognosis is tied to the underlying cancer rather than the skin condition itself. Drug-induced cases tend to resolve completely once the triggering medication is discontinued.